Diametric Capital, LP Sarepta Therapeutics, Inc. Transaction History

Diametric Capital, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $267,138 - $403,502	-2,851 Reduced 62.41%	1,717 $222,000
Q4 2023 Feb 13, 2024	SELL	$67.31 - $124.76 $1.15 Million - $2.13 Million	-17,089 Reduced 78.91%	4,568 $440,000
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $872,992 - $1.05 Million	8,517 Added 64.82%	21,657 $2.63 Million
Q2 2023 Aug 11, 2023	BUY	$106.4 - $157.19 $769,165 - $1.14 Million	7,229 Added 122.3%	13,140 $1.5 Million
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $694,719 - $922,056	5,911 New	5,911 $814,000
Q3 2020 Nov 13, 2020	SELL	$127.12 - $172.34 $733,990 - $995,091	-5,774 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $245,985 - $454,146	2,645 Added 84.53%	5,774 $926,000
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $257,767 - $411,901	3,129 New	3,129 $306,000
Q3 2019 Nov 13, 2019	SELL	$72.81 - $156.91 $118,971 - $256,390	-1,634 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $204,222 - $276,549	-1,820 Reduced 52.69%	1,634 $248,000
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $147,844 - $210,228	1,386 Added 67.02%	3,454 $412,000
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $36,884 - $56,380	379 Added 22.44%	2,068 $225,000
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $194,758 - $272,790	1,689 New	1,689 $273,000
Q2 2018 Aug 14, 2018	SELL	$71.74 - $153.69 $562,441 - $1.2 Million	-7,840 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $655,910 - $998,922	-12,142 Reduced 60.76%	7,840 $581,000
Q4 2017 Feb 14, 2018	BUY	$47.64 - $56.75 $951,942 - $1.13 Million	19,982	19,982 $1.11 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.